Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has disrupted health care and has resulted in high mortality rates.(1) Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Millie D., Weaver, Kimberly N., Zhang, Xian, Chun, Kelly, Kappelman, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the AGA Institute 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826602/
https://www.ncbi.nlm.nih.gov/pubmed/35150924
http://dx.doi.org/10.1016/j.cgh.2022.01.056
_version_ 1784647459905994752
author Long, Millie D.
Weaver, Kimberly N.
Zhang, Xian
Chun, Kelly
Kappelman, Michael D.
author_facet Long, Millie D.
Weaver, Kimberly N.
Zhang, Xian
Chun, Kelly
Kappelman, Michael D.
author_sort Long, Millie D.
collection PubMed
description The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has disrupted health care and has resulted in high mortality rates.(1) Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individuals with immunocompromising conditions.(2)
format Online
Article
Text
id pubmed-8826602
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher by the AGA Institute
record_format MEDLINE/PubMed
spelling pubmed-88266022022-02-10 Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases Long, Millie D. Weaver, Kimberly N. Zhang, Xian Chun, Kelly Kappelman, Michael D. Clin Gastroenterol Hepatol Research Letter The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has disrupted health care and has resulted in high mortality rates.(1) Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individuals with immunocompromising conditions.(2) by the AGA Institute 2022-08 2022-02-09 /pmc/articles/PMC8826602/ /pubmed/35150924 http://dx.doi.org/10.1016/j.cgh.2022.01.056 Text en © 2022 by the AGA Institute. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Research Letter
Long, Millie D.
Weaver, Kimberly N.
Zhang, Xian
Chun, Kelly
Kappelman, Michael D.
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases
title Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases
title_full Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases
title_fullStr Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases
title_full_unstemmed Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases
title_short Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases
title_sort strong response to sars-cov-2 vaccine additional doses among patients with inflammatory bowel diseases
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826602/
https://www.ncbi.nlm.nih.gov/pubmed/35150924
http://dx.doi.org/10.1016/j.cgh.2022.01.056
work_keys_str_mv AT longmillied strongresponsetosarscov2vaccineadditionaldosesamongpatientswithinflammatoryboweldiseases
AT weaverkimberlyn strongresponsetosarscov2vaccineadditionaldosesamongpatientswithinflammatoryboweldiseases
AT zhangxian strongresponsetosarscov2vaccineadditionaldosesamongpatientswithinflammatoryboweldiseases
AT chunkelly strongresponsetosarscov2vaccineadditionaldosesamongpatientswithinflammatoryboweldiseases
AT kappelmanmichaeld strongresponsetosarscov2vaccineadditionaldosesamongpatientswithinflammatoryboweldiseases
AT strongresponsetosarscov2vaccineadditionaldosesamongpatientswithinflammatoryboweldiseases

Ejemplares similares